Clay Siegall was recently appointed to Minra Therapeutics’ Board of Directors. Minra is a biotechnology firm, which focuses on the advancement and commercialization of pharmaceutical products. Siegall will serve as an external director on the firm’s board. The firm’s chief executive officer and president, Dr. Paul Lammers expressed his delight at Siegall’s appointment. The success that he has had within the industry will help open new doors for Minra.
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
Minra has made a name for itself through the advancement of a MicroRNA-based therapy, which is used in cancer treatment. Dr. Siegall himself expressed his delight with the appointment. He looks forward to using his research to enhance cancer research. The experience that he has had in building biotechnology firms will similarly help in advancing programs that benefit cancer patients.
Minra Therapeutics has created a niche for itself in the industry due to its groundbreaking products. It has a highly trained team of in-house scientists, who have helped it to build an impressive intellectual property portfolio. The firm has grown incredibly due to the networks that it has formed within and beyond the industry. Its board of directors is composed of proven industry heads, whose experience has been of great benefit to the firm.
Dr. Siegall in Brief
He is regarded as one of the most successful biotechnologists of his generation. Dr. Clay Siegall started Seattle Genetics in 1998. He wanted to advance cost-effective cancer therapies. The leadership that he has provided throughout the years has helped the company to build a highly diversified network. Seattle Genetics boasts an extraordinary product portfolio. It is credited with advancing anti-body based cancer therapies, which are used in more than 70 countries.
The firm is synonymous with ADCETRIS, which is its flagship commercial product. It was approved in 2011 and has gone on to become the one of the best cancer therapies. To fund Seattle Genetics’ research activities, Dr. Siegall has used his unique fundraising skills to raise more than 675 million dollars on behalf of the firm. Due to the legendary status that he has within the industry, Clay sits on the boards of different companies. He is also a publisher, with over 70 publications under his name.